Today: 7 February 2026
Subscribe
Browse Category

Biotech Stocks News 31 December 2025 - 2 February 2026

Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next

Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next

Soleno Therapeutics shares jumped 8.9% to $42.00 Monday, outpacing a broad biotech rally. The move follows attention on VYKAT XR’s U.S. launch, with preliminary 2025 revenue reported at up to $191 million and 1,250 patient starts. Investors are awaiting full financial results in late February and monitoring upcoming investor conference appearances. No new company news was released Monday.
2 February 2026
·····
Perspective Therapeutics stock (CATX) steadies before the open after 66% jump — what investors watch next

Perspective Therapeutics stock (CATX) steadies before the open after 66% jump — what investors watch next

Perspective Therapeutics shares slipped 0.8% to $4.22 in early premarket trading Friday after surging 66.4% the previous day, with volume topping 69 million shares. The stock’s sharp moves follow recent clinical updates and filings, but no new disclosures drove Thursday’s spike. Traders are watching for further swings as the regular session opens. Next earnings report is scheduled for March 26.
30 January 2026
·····
Regencell Bioscience (RGC) stock drops 20% in Nasdaq trade as volatility flares again

Regencell Bioscience (RGC) stock drops 20% in Nasdaq trade as volatility flares again

New York, Jan 13, 2026, 14:12 EST — Regular session Shares of Regencell Bioscience Holdings Limited dropped over 20% on Tuesday, continuing a volatile streak that has kept the Nasdaq-listed microcap in the spotlight on momentum trackers. The decline is significant because the stock has proven it can swing sharply with little notice, a pattern that can catch late buyers off guard and trigger rapid sell-offs when liquidity dries up. The spotlight returns to what usually moves this stock daily: price action and positioning, rather than a steady stream of news. Investors are asking less “what changed” and more “how
13 January 2026
····
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

New York, Jan 12, 2026, 14:53 EST — Regular session. Sarepta Therapeutics shares dropped roughly 13% to $20.73 in Monday afternoon trading following a disappointing sales forecast for its Duchenne muscular dystrophy gene therapy, Elevidys, in the fourth quarter. This matters because Elevidys has turned into the company’s key swing factor — and a closely watched one at that — for a stock that’s already been tossed around by safety concerns and shifts in treatment protocols over the past year. The timing coincides with the J.P. Morgan Healthcare Conference, where investors usually demand clear guidance and early insights for the
12 January 2026
····
NovaBay Pharmaceuticals stock doubles as NBY volatility flares again — what to watch next

NovaBay Pharmaceuticals stock doubles as NBY volatility flares again — what to watch next

New York, January 10, 2026, 18:35 EST — Market closed Shares of NovaBay Pharmaceuticals Inc soared on Friday, closing up roughly 103% at $19.16. Over 10 million shares changed hands, market data showed. NovaBay is back on momentum screens before the next U.S. session, trading in a price range unseen for over a year. Why it matters now: NovaBay’s size means its price often moves on volume, not news. When that shift hits before a weekend, the following open becomes a gauge of who’s left to buy. The stock moved between $9.69 and $19.95 in regular trading, then was last
11 January 2026
·····
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

New York, Jan 9, 2026, 13:28 (EST) — Regular session Soleno Therapeutics shares slid on Friday, extending a choppy stretch for the rare-disease drugmaker. The stock was down 5.6% at $42.95, after touching a low of $42.73, while the SPDR S&P Biotech ETF was up about 1.1%. The move matters now because Soleno’s story still hinges on a young commercial launch and a single product, Vykat XR. Any shift in sentiment around safety, pricing, or patients staying on therapy can hit the stock hard, fast. A Zacks Equity Research industry outlook on Thursday highlighted Soleno alongside Nektar Therapeutics, Rigel Pharmaceuticals,
9 January 2026
···
Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

New York, Jan 7, 2026, 10:56 EST — Regular session Regencell Bioscience Holdings Limited shares jumped about 27% to $41.90 in morning trading on Wednesday, extending a sharp two-day run for the Nasdaq-listed microcap. The stock has swung between $34.11 and $43.74 so far in the session, with nearly 1.0 million shares traded. Why it matters now: the move builds on Tuesday’s 22% gain and keeps Regencell near the top of the day’s high-volatility names, even by small-cap standards. The stock closed at $33.03 on Tuesday after trading as high as $35.68, following a $27.00 close on Monday. StockAnalysis The
7 January 2026
··
Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

New York, Jan 7, 2026, 11:04 EST — Regular session Shares of Crinetics Pharmaceuticals rose about 16% to $53.40 on Wednesday, after the biotech priced a $350 million stock offering and detailed early U.S. launch metrics for its newly approved acromegaly drug. Crinetics said it generated preliminary, unaudited net product revenue of more than $5 million from PALSONIFY in the fourth quarter of 2025, with more than 200 enrollment forms and over 125 unique prescribers by the end of December. It also posted Phase 2 results for atumelnant in congenital adrenal hyperplasia (CAH), reporting a 67% mean reduction in androstenedione
7 January 2026
·····
Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

NEW YORK, January 4, 2026, 13:49 ET — Market closed Dyne Therapeutics shares closed down 5.5% on Friday at $18.50, ending the first U.S. trading session of 2026 on a softer note. About 2.65 million shares changed hands. The pullback matters because 2026 is shaping up as a timing-driven year for the clinical-stage biotech, with investors focused on whether its lead Duchenne muscular dystrophy program can reach regulators on schedule and on what that path costs. Dyne said in December its Phase 1/2 DELIVER trial met its main biomarker goal, lifting dystrophin — a muscle protein missing in Duchenne —
4 January 2026
·····
Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

New York, Jan 4, 2026, 12:46 ET — Market closed Wave Life Sciences shares closed down 6.2% on Friday at $15.95, with the Nasdaq-listed biotech swinging between $15.53 and $17.23 in the session. The drop matters because Wave’s stock has become a high-beta proxy for investor appetite for next-generation obesity treatments, where early clinical signals can move valuations sharply. The next company update investors care about is already on the calendar: Wave has guided to additional INLIGHT trial data in the first quarter. SEC Wave is developing RNA medicines, including WVE-007, a small interfering RNA (siRNA) therapy that aims to
4 January 2026
·····
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

NEW YORK, December 31, 2025, 18:31 ET — After-hours Corcept Therapeutics Inc shares sank about 50% in after-hours trading on Wednesday after the U.S. Food and Drug Administration declined to approve its oral drug relacorilant for a Cushing’s-related hypertension use. The stock was last at $34.80, down $35.39 from the prior close. Reuters The decision hits at a key moment for Corcept, which investors have looked to relacorilant to expand the company’s business beyond its marketed drug Korlym. A regulatory setback for relacorilant raises the risk that Corcept’s next growth driver takes longer—and costs more—to reach the market. Reuters Corcept
1 January 2026
····
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

NEW YORK, December 31, 2025, 11:19 ET — Regular session Abivax Société Anonyme’s U.S.-listed American depositary shares (ABVX) fell about 3.8% to $133.04, down roughly $5.30 from Tuesday’s close, in late morning trade on Wednesday. The shares opened at $138 and swung between $132.13 and $140.25, with about 348,000 shares traded. The pullback keeps the spotlight on ABVX after takeover chatter earlier this month. Reuters reported on Dec. 10 that Abivax jumped on market rumours that Eli Lilly could make an offer, and Stifel analyst Damien Choplain said the “share price movement is driven by speculation around a possible takeover.”
31 December 2025
····
1 2 3 … 6

Stock Market Today

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

7 February 2026
Beazley shares closed flat at 1,236 pence Friday as BlackRock disclosed a 6.55% stake and Vanguard reported 5.02%. Wellington Management cut its holding below 5%. The disclosures follow Zurich Insurance’s possible takeover offer of up to 1,335 pence per share, with a Feb. 16 deadline for a firm bid.
Go toTop